Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29895835 | 1.00 | HTT (0.50) | HTTMAPTLMNAKDM4EPIK3CA | |
| SCHEMBL29980324 | 0.92 | LMNA (0.49) | HTTMAPTLMNAKDM4EPIK3CA | |
| SCHEMBL11519 | 0.89 | LMNA (0.55) | HTTMAPTLMNAKDM4EPIK3CA | |
| SCHEMBL11100 | 0.88 | HPGD (0.47) | HTTMAPTLMNAKDM4EPIK3CA | |
| SCHEMBL30494456 | 0.88 | HPGD (0.47) | HTTMAPTLMNAKDM4EPIK3CA | |
| SCHEMBL149865 | 0.87 | HTT (0.61) | HTTMAPTLMNAKDM4EPIK3CA | |
| SCHEMBL10560970 | 0.87 | LMNA (0.54) | HTTMAPTLMNAKDM4EPIK3CA | |
| SCHEMBL10561782 | 0.86 | PIK3CA (0.68) | HTTMAPTLMNAKDM4EPIK3CA | |
| SCHEMBL29980557 | 0.78 | LMNA (0.45) | HTTMAPTLMNAKDM4EPIK3CA | |
| SCHEMBL10592586 | 0.77 | HTT (0.47) | HTTMAPTLMNAKDM4EPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | claimed |
| US-20240360095-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-20210403475-A1 | NOVEL SELECTIVE PI3K DELTA INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2021-12-30 | — | — | US | disclosed |
| US-10981919-B2 | Selective PI3K delta inhibitors | RHIZEN PHARMACEUTICALS SA (CH) | 2021-04-20 | — | — | US | disclosed |
| EP-3756686-A1 | COMBINATION OF ANTI-CD20 ANTIBODY AND PI3 KINASE SELECTIVE INHIBITOR | TG Therapeutics Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| US-20200323981-A1 | Combination of Anti-CD20 Antibody and PI3 Kinase Selective Inhibitor | BLUE OWL CAPITAL CORPORATION | 2020-10-15 | — | — | US | disclosed |
| US-20200270258-A1 | NOVEL SELECTIVE PI3K DELTA INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2020-08-27 | — | — | US | disclosed |
| US-10729768-B2 | Combination of anti-CD20 antibody and PI3 kinase selective inhibitor | TG THERAPEUTICS, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-20200239427-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2020-07-30 | — | — | US | disclosed |
| US-20150174131-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2015-06-25 | — | — | US | disclosed |
| EP-2870157-A1 | SELECTIVE PI3K DELTA INHIBITORS | Rhizen Pharmaceuticals S.A. (CH) | 2015-05-13 | — | — | EP | disclosed |
| US-9018375-B2 | Substituted chromenes as kinase modulators | RHIZEN PHARMACEUTICALS SA (CH) | 2015-04-28 | — | — | US | disclosed |
| WO-2014071125-A1 | COMBINATION OF ANTI-CD20 ANTIBODY AND PI3 KINASE SELECTIVE INHIBITOR | TG THERAPEUTICS, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| US-20140080827-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2014-03-20 | — | — | US | disclosed |
| US-8642607-B2 | 4H-chromen-4-one compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2014-02-04 | — | — | US | disclosed |
| US-20140011819-A1 | NOVEL SELECTIVE PI3K DELTA INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2014-01-09 | — | — | US | disclosed |
| WO-2014006572-A1 | SELECTIVE PI3K DELTA INHIBITORS | RHIZEN PHARMACEUTICALS SA (CH) | 2014-01-09 | — | — | WO | disclosed |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2012-03-08 | — | — | US | disclosed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200323981-A1 | Combination of Anti-CD20 Antibody and PI3 Kinase Selective Inhibitor | PIK3R4, PIK3R5, PIK3R1 | HTT 3643/4885MAPT 2946/4885LMNA 3677/4885 |
| US-20150174131-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | HTT 3125/4885MAPT 2989/4885LMNA 2326/4885 |
| US-20240360095-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | HTT 3125/4885MAPT 2989/4885LMNA 2326/4885 |
| US-20140011819-A1 | NOVEL SELECTIVE PI3K DELTA INHIBITORS | PIK3CD, PIK3R5, PIK3C2B | HTT 3496/4885MAPT 3869/4885LMNA 2130/4885 |
| US-20140080827-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | HTT 3125/4885MAPT 2989/4885LMNA 2326/4885 |
| US-20200270258-A1 | NOVEL SELECTIVE PI3K DELTA INHIBITORS | PIK3CD, PIK3R5, PIK3C2B | HTT 3496/4885MAPT 3869/4885LMNA 2130/4885 |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | HTT 3125/4885MAPT 2989/4885LMNA 2326/4885 |
| US-10729768-B2 | Combination of anti-CD20 antibody and PI3 kinase selective inhibitor | PIK3R4, PIK3R5, PIK3CD | HTT 3165/4885MAPT 1765/4885LMNA 4164/4885 |
| US-20200239427-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | HTT 3125/4885MAPT 2989/4885LMNA 2326/4885 |
| US-10981919-B2 | Selective PI3K delta inhibitors | PIK3CD, PIK3C2B, PIK3R5 | HTT 3615/4885MAPT 4133/4885LMNA 1778/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | HTT 3291/4885MAPT 3674/4885LMNA 1277/4885 |
| US-20210403475-A1 | NOVEL SELECTIVE PI3K DELTA INHIBITORS | PIK3CD, PIK3R5, PIK3C2B | HTT 3496/4885MAPT 3869/4885LMNA 2130/4885 |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | HTT 3125/4885MAPT 2989/4885LMNA 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.